510(k) Clearance Received for Endoform® Plastics and Reconstructive Matrix20 Dec 2016
Aroa Biosurgery has been granted U.S. Food and Drug Administration (FDA) 510(k) clearance for the company’s Endoform® Plastics and Reconstructive Matrix, which allows the company to market and sell this device in the USA.
Continue ReadingAroa Biosurgery successfully raises additional capital to fund growth14 Oct 2016
Aroa Biosurgery has successfully raised additional capital from new and existing investors from the USA, Australia and New Zealand.
Continue ReadingLaunch of Ovitex Reinforced Bioscaffolds13 Jul 2016
Aroa Biosurgery’s partner, TelaBio, Inc. announced today, the commercial launch of the Ovitex™ Reinforced Bioscaffolds (“RBS”) portfolio of products for use in ventral hernia repair and abdominal wall reconstruction in the USA.
Continue Reading